A network-based method for mechanistic investigation of Shexiang Baoxin Pill’s treatment of cardiovascular diseases

Shexiang Baoxin Pill (SBP), a traditional Chinese medicine formula, is commonly used to treat cardiovascular disease (CVD) in China. However, the complexity of composition and targets has deterred our understanding of its mechanism of action. Using network pharmacology-based approaches, we establish...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Hai-Yang, Zeng, Hua-Wu, Lin, Li-Mei, Chen, Xing, Shen, Xiao-Na, Fu, Peng, Lv, Chao, Liu, Qun, Liu, Run-Hui, Zhang, Wei-Dong, Zhao, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341564/
https://www.ncbi.nlm.nih.gov/pubmed/28272527
http://dx.doi.org/10.1038/srep43632
Descripción
Sumario:Shexiang Baoxin Pill (SBP), a traditional Chinese medicine formula, is commonly used to treat cardiovascular disease (CVD) in China. However, the complexity of composition and targets has deterred our understanding of its mechanism of action. Using network pharmacology-based approaches, we established the mechanism of action for SBP to treat CVD by analyzing protein-protein interactions and pathways. The computational results were confirmed at the gene expression level in microarray-based studies. Two of the SBP’s targets were further confirmed at the protein level by Western blot. In addition, we validated the theory that SBP’s plasma absorbed compounds play major therapeutic role in treating CVD.

Ejemplares similares